CN113924091A - 治疗肿瘤的方法 - Google Patents

治疗肿瘤的方法 Download PDF

Info

Publication number
CN113924091A
CN113924091A CN202080042217.2A CN202080042217A CN113924091A CN 113924091 A CN113924091 A CN 113924091A CN 202080042217 A CN202080042217 A CN 202080042217A CN 113924091 A CN113924091 A CN 113924091A
Authority
CN
China
Prior art keywords
compound
tumor
alkyl
alkenyl
epoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080042217.2A
Other languages
English (en)
Chinese (zh)
Inventor
V·A·戈登
P·W·雷德尔
G·M·博伊尔
J·K·库伦
P·G·帕森斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QBiotics Pty Ltd
Original Assignee
QBiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901280A external-priority patent/AU2019901280A0/en
Application filed by QBiotics Pty Ltd filed Critical QBiotics Pty Ltd
Publication of CN113924091A publication Critical patent/CN113924091A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080042217.2A 2019-04-12 2020-04-09 治疗肿瘤的方法 Pending CN113924091A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019901280 2019-04-12
AU2019901280A AU2019901280A0 (en) 2019-04-12 Method of Treatment
PCT/AU2020/050360 WO2020206504A1 (en) 2019-04-12 2020-04-09 Method of treating tumours

Publications (1)

Publication Number Publication Date
CN113924091A true CN113924091A (zh) 2022-01-11

Family

ID=72752169

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080042217.2A Pending CN113924091A (zh) 2019-04-12 2020-04-09 治疗肿瘤的方法

Country Status (26)

Country Link
US (1) US12226391B2 (https=)
EP (1) EP3952858B1 (https=)
JP (2) JP2022528915A (https=)
KR (1) KR20210152531A (https=)
CN (1) CN113924091A (https=)
AU (1) AU2020256847B2 (https=)
BR (1) BR112021020253A2 (https=)
CA (1) CA3136216C (https=)
DK (1) DK3952858T3 (https=)
EA (1) EA202192757A1 (https=)
ES (1) ES3063750T3 (https=)
FI (1) FI3952858T3 (https=)
HR (1) HRP20260232T1 (https=)
IL (1) IL287210B2 (https=)
LT (1) LT3952858T (https=)
MX (1) MX2021012449A (https=)
MY (1) MY208979A (https=)
PL (1) PL3952858T3 (https=)
PT (1) PT3952858T (https=)
RS (1) RS67777B1 (https=)
SG (1) SG11202110599RA (https=)
SI (1) SI3952858T1 (https=)
SM (1) SMT202600066T1 (https=)
UA (1) UA129840C2 (https=)
WO (1) WO2020206504A1 (https=)
ZA (1) ZA202108677B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597019A (en) * 2005-12-23 2013-11-29 Qbiotics Ltd Tiglien-3-one derivatives
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
IL289072B2 (en) 2019-06-19 2025-06-01 QBiotics Pty Ltd Biofilm disruption
JP2024546296A (ja) * 2021-12-21 2024-12-19 キューバイオティクス プロプライアタリー リミティド 結晶性中間体
CN120569368A (zh) * 2022-12-21 2025-08-29 Q生物股份有限公司 晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101384575A (zh) * 2005-12-23 2009-03-11 Q生物有限公司 巴豆烯-3-酮衍生物
WO2018018097A1 (en) * 2016-07-28 2018-02-01 Qbiotics Limited Method of treatment
WO2018170559A1 (en) * 2017-03-23 2018-09-27 Qbiotics Limited Combination therapy for the treatment or prevention of tumours

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA118670C2 (uk) * 2013-04-18 2019-02-25 К'Юбайотікс Лімітед Способи та композиції для загоєння ран

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101384575A (zh) * 2005-12-23 2009-03-11 Q生物有限公司 巴豆烯-3-酮衍生物
WO2018018097A1 (en) * 2016-07-28 2018-02-01 Qbiotics Limited Method of treatment
WO2018170559A1 (en) * 2017-03-23 2018-09-27 Qbiotics Limited Combination therapy for the treatment or prevention of tumours

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GLEN M. BOYLE等: "Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models", PLOS ONE, vol. 9, no. 10, pages 1 *

Also Published As

Publication number Publication date
LT3952858T (lt) 2026-04-10
US20220193023A1 (en) 2022-06-23
IL287210B2 (en) 2025-07-01
AU2020256847A1 (en) 2021-11-11
PT3952858T (pt) 2026-02-26
IL287210B1 (en) 2025-03-01
SG11202110599RA (en) 2021-10-28
CA3136216A1 (en) 2020-10-15
EP3952858A1 (en) 2022-02-16
EP3952858B1 (en) 2025-12-17
ES3063750T3 (en) 2026-04-20
WO2020206504A1 (en) 2020-10-15
SMT202600066T1 (it) 2026-03-09
JP2022528915A (ja) 2022-06-16
ZA202108677B (en) 2026-03-25
AU2020256847B2 (en) 2025-05-15
IL287210A (en) 2021-12-01
US12226391B2 (en) 2025-02-18
DK3952858T3 (da) 2026-02-23
RS67777B1 (sr) 2026-03-31
JP2025060945A (ja) 2025-04-10
MY208979A (en) 2025-06-14
HRP20260232T1 (hr) 2026-03-27
PL3952858T3 (pl) 2026-03-30
EA202192757A1 (ru) 2022-02-11
FI3952858T3 (fi) 2026-02-18
MX2021012449A (es) 2021-11-12
CA3136216C (en) 2024-01-16
EP3952858A4 (en) 2022-05-25
KR20210152531A (ko) 2021-12-15
UA129840C2 (uk) 2025-08-20
BR112021020253A2 (pt) 2021-12-07
SI3952858T1 (sl) 2026-04-30

Similar Documents

Publication Publication Date Title
EP3952858B1 (en) Method of treating tumours
JP6905075B2 (ja) 腫瘍の治療または予防のための併用療法
US11730803B2 (en) Cancer immunotherapy using virus particles
JP2021191781A (ja) フラジェリン組成物および使用
RU2728101C2 (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
KR20240148417A (ko) 조합 치료법
HK40060616A (en) Method of treating tumours
HK40060616B (en) Method of treating tumours
WO2021159547A1 (zh) 一种预防和/或治疗卵巢癌的多肽药物及其用途
EA044461B1 (ru) Способ лечения опухолей
CN109674788B (zh) 羧胺三唑与ido1抑制剂组合在抗肿瘤中的用途
EA044756B1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
Bramante et al. 438. Oncolytic Immunotherapy for Treatment of Breast Cancer, Including Triple-Negative Breast Cancer
Hamada et al. 437. Biosafety After the Injection of Carrier Cells Infected With Oncolytic Adenovirus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination